Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03934333 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT03934333 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 11 participants.
The verdict
NCT03934333, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study is to compare the systemic exposure of budesonide delivered by the combination inhaler (budesonide/albuterol sulfate pressurized inhalation suspension \[BDA metered dose inhaler {BDA MDI}\]) with Pulmicort Flexhaler dry-powder inhaler (DPI).
Interventions
- DRUG BDA MDI 160/180 mcg
- DRUG Pulmicort Flexhaler 180 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2019-05-16 |
| Est. Completion | 2019-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03934333
The ClinicalTrials.gov registry entry for NCT03934333 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BDA MDI 160/180 mcg is the first listed.
NCT03934333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03934333 about?
NCT03934333 is a clinical study titled "A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)". This study is to compare the systemic exposure of budesonide delivered by the combination inhaler (budesonide/albuterol sulfate pressurized inhalation suspension \[BDA metered dose inhaler {BDA MDI}\]) with Pulmicort Flexhaler dry-powder inhaler (DPI).
What is the current status of trial NCT03934333?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2019-05-16. Estimated completion is 2019-09-10.
What interventions are being tested in trial NCT03934333?
The interventions under investigation include: BDA MDI 160/180 mcg (DRUG), Pulmicort Flexhaler 180 mcg (DRUG).
Who is sponsoring clinical trial NCT03934333?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.